Tirzepatide outperforms other GLP-1 drugs in diabetes for blood sugar and weight loss

Key Takeaways: 

• Tirzepatide demonstrated the strongest reductions in HbA1c and body weight among all GLP-1 RAs analysed, outperforming even Semaglutide and Liraglutide.
• Gastrointestinal side effects were common across long-acting agents, while hypoglycaemia risk varied, with Liraglutide offering a safer profile for some individuals.
• The findings reinforce a clinical shift towards long-acting and dual agonist therapies for managing type 2 diabetes, offering guidance for clinicians, payers, and policymakers.
  

Growing burden of type 2 diabetes drives search for optimal treatments

Every ten seconds, someone around the globe develops type 2 diabetes mellitus (T2DM) — a chronic disease that substantially raises household healthcare costs and doubles the risk of cardiovascular events such as heart attacks. The worldwide prevalence is projected to soar to 643 million by 2030, intensifying the need for treatments that lower blood glucose levels without contributing to weight gain.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) both stimulate insulin secretion and suppress appetite. However, with a crowded marketplace of differing doses, formulations, and costs, families, clinicians, and health systems continue to seek the medication that offers maximum benefit with minimal drawbacks. This underscores the importance of robust comparative studies.

Rigorous study design to compare eight GLP-1 RAs

In a comprehensive study recently published in Scientific Reports, researchers undertook a systematic review and Bayesian network meta-analysis (NMA) to evaluate the glycaemic, weight, cardiovascular, and safety outcomes of eight GLP-1 RAs. The analysis compared these agents to placebo and standard antidiabetic drugs in adults living with T2DM.

The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Network Meta-Analyses (PRISMA-NMA) guidelines and was registered with the International Prospective Register of Systematic Reviews. The research team systematically searched PubMed, Cochrane Library, Embase, Web of Science, and Chinese databases up to 2 October 2024.

Eligible studies were randomised controlled trials (RCTs) lasting at least eight weeks, involving adults with T2DM. These trials compared twice-daily Exenatide (EBID), once-weekly Exenatide (EQW), Semaglutide, Albiglutide, Lixisenatide, Dulaglutide, Liraglutide, or Tirzepatide against each other, placebo, or traditional antidiabetic agents such as insulin, metformin, sodium-dependent glucose transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas.

For analysis, oral and injectable Semaglutide were grouped due to their comparable efficacy. Independent reviewers conducted study selection, data extraction, and Cochrane risk-of-bias assessments, resolving any differences through consensus.

Outcomes assessed and statistical approach

The primary outcomes were changes from baseline in glycosylated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG). Secondary outcomes included changes in body weight, body mass index (BMI), systolic and diastolic blood pressure (SBP, DBP), total cholesterol (TC), high-density and low-density lipoprotein cholesterol (HDL-C, LDL-C), and reported adverse events.

Mean differences (MD) or risk ratios (RR) were calculated with 95% confidence intervals (CIs). When heterogeneity exceeded 50% (as measured by I²), a random-effects model was applied, with Chi-squared tests used to quantify variability.

Tirzepatide shows leading benefits in blood glucose and weight outcomes

From 64 eligible trials involving 25,572 participants, a dense evidence network emerged. Compared with placebo, all GLP-1 RAs lowered HbA1c, but the extent varied markedly:

• Tirzepatide achieved the largest absolute HbA1c reduction (MD −2.3 percentage points; 95% CI −2.7 to −1.9), followed by Semaglutide (−1.5) and Liraglutide (−1.2).
• Lixisenatide’s modest reduction of −0.56 placed it last.
  

When compared to a pooled group of conventional drugs (including insulin, metformin, SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas), only Tirzepatide (−1.5), Semaglutide (−0.73), Liraglutide (−0.40), Dulaglutide (−0.34), and EQW (−0.36) demonstrated statistically significant superiority.

A similar hierarchy was evident for FPG reductions: Tirzepatide lowered FPG by −3.1 mmol/L, followed by Semaglutide (−2.0) and Liraglutide (−1.6). Short-acting agents and Albiglutide offered negligible improvements. The Surface Under the Cumulative Ranking Curve analysis gave Tirzepatide a 100% probability of being the top agent for glycaemic outcomes.

Marked differences in weight outcomes

The weight loss data revealed even starker contrasts. Compared to placebo:

• Tirzepatide achieved a striking −9.1 kg reduction,
• Semaglutide −2.8 kg,
• EBID −1.8 kg, and
• Liraglutide −1.2 kg.
  

Notably, EBID outperformed Liraglutide in this comparison. When benchmarked against traditional drugs, all GLP-1 RAs except Albiglutide reduced weight, with Dulaglutide and Lixisenatide also showing meaningful effects. Tirzepatide again led with a −10 kg difference.

Changes in blood pressure, BMI, and lipid fractions did not reach statistical significance across interventions, suggesting that glucose and weight benefits did not yet translate into short-term shifts in these cardiovascular parameters.

Safety profile: balancing gastrointestinal effects and hypoglycaemia risk

Gastrointestinal side effects were the most common adverse events. Compared with placebo:

• Semaglutide, Dulaglutide, Liraglutide, Lixisenatide, and Tirzepatide each tripled the risk of nausea and vomiting.
• However, when compared to older drugs already known for gastrointestinal intolerance, the risks were similar.
  

Hypoglycaemia risk varied considerably:

• EBID and Semaglutide significantly increased episodes (RR 3.3 and 4.6, respectively) versus placebo.
• In contrast, Liraglutide and Lixisenatide actually reduced hypoglycaemia risk compared with traditional regimens, highlighting a possible advantage for people prone to low blood sugar.
  

Other side effects, such as nasopharyngitis, headache, and elevated lipase levels, showed no material differences. Robust statistical checks (node-splitting, loop inconsistency tests) found no significant discrepancies between direct and indirect comparisons, and funnel plots suggested low publication bias.

Clinical implications and concluding remarks

This analysis positions Tirzepatide as the most effective agent overall for lowering blood glucose and achieving weight loss, with Semaglutide as a reliable second choice. As the authors note, Tirzepatide’s dual agonist activity at GIP and GLP-1 receptors likely underpins its superior outcomes.

Meanwhile, Liraglutide offers moderate glucose improvements with the least risk of hypoglycaemia, potentially making it preferable for leaner adults or those at risk of underweight and frequent hypoglycaemic episodes.

Short-acting formulations and Albiglutide rarely dominated in any category, emphasising the current shift towards once-weekly or dual agonist therapies. Sensitivity and subgroup analyses confirmed these rankings, increasing their practical relevance.

For clinicians, these findings offer valuable guidance in tailoring treatment to individual needs — balancing glucose targets, weight goals, gastrointestinal tolerance, and hypoglycaemia risk. For policymakers and payers, prioritising agents like Tirzepatide or Semaglutide may provide the best outcomes for people with obesity-related diabetes, while reserving Liraglutide for specific patient profiles.